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Rheumatoid arthritisAbstract Aim of the work: To estimate the prevalence of depression and its relationship with dis-
ease activity parameters in Egyptian patients with RA.
Patients and methods: A cross sectional study was conducted on 170 patients with RA. The fol-
lowing values were assessed for each patient: erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP), rheumatoid factor (RF), swollen and tender joint counts (SJC and TJC), disease activity
score 28 (DAS28), health assessment questionnaire score (HAQ), visual analogue scale (VAS) of
pain and hospital anxiety and depression scale-depression subscale (HADS-D).
Results: The prevalence of depression was 15.29% (26 RA patients). In the depressed RA
patients, positive signiﬁcant correlations were found between HADS-D score and age, disease dura-
tion, HAQ score, VAS, DAS28 score and CRP. However, no signiﬁcant correlation was found
between HADS-D score and ESR, number of swollen and tender joints. No signiﬁcant difference
(P> 0.05) was found between depressed male and female patients with RA.
Conclusion: Patients with RA and co-morbid depression have worse health outcomes. RA cases
should be monitored for accompanying depression during follow-up. The identiﬁcation and treat-
ment of depression in RA paramount to the overall management of RA.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is a multifactorial, chronic, inﬂam-
matory disease affecting primarily the joints with prevalence of
between 0.5% and 1% [1]. Pain, fatigue and disability, which
may be considered as stress factors [2], are common challenges
that may subsequently lead to psychological distress [3].
Depression commonly co-occurs with RA, in the range of
13–20% and above based on clinical assessments [4]. Studies
194 H. Mostafa, A. Radwanusing self report measures of depressive symptoms suggest
considerably higher rates (i.e. 40%), although the levels of
symptomatology may be subclinical [5]. The prevalence rates
of depression in RA are well above those reported in the gen-
eral community (2–4%) or primary care (5–10%) but similar
to other chronic conditions [6]. Depression in RA is associated
with higher levels of disease activity, pain, fatigue, work dis-
ability, health service use but lower treatment compliance [7]
and increased suicide risk [8] and mortality [9].
Regular mood assessment by rheumatology clinical staff
may serve to improve awareness and early identiﬁcation of
depression [7] and thus timely identiﬁcation and treatment of
depression in RA are critical to overall clinical management
[10]. While not substituting for a psychiatric clinical assess-
ment, the use of self-report scales may be a feasible option in
rheumatology settings to identify patients at risk of depression.
Regular screening, and early intervention or appropriate refer-
ral, where necessary, would provide a psychological ‘window
of opportunity’ akin to that recommended in relation to clini-
cal treatment of early RA [11].
While a number of screening instruments for depression are
available, one of the most commonly used scales is the hospital
anxiety and depression scale (HADS) [12]. The HADS was
developed for use in hospital settings, with items chosen to re-
duce contamination with somatic or disease related symptoms.
This scale has been used with RA populations and has been
subjected to psychometric assessment of their reliability and
validity including exploratory and conﬁrmatory factor analy-
ses [11,13–15].
This study was undertaken to estimate the prevalence of
depression and its relationship with disease activity parameters
in Egyptian patients with RA.
2. Patients and methods
This cross-sectional study was conducted on RA patients
attending the outpatient clinic of Rheumatology and Rehabil-
itation department, Sohag University Hospital, in the period
between October 2012 and March 2013. A total of 170 patients
(female/male = 153/17) fulﬁlling the American College of
Rheumatology (ACR) criteria for a diagnosis of RA [16] with
a mean age of 43.75 ± 8.03 years were studied. The study in-
cluded only RA patients with onset of depression following
established diagnosis of RA. Excluded from our study were
RA patients with history of previous psychiatric disorders,
present chronic disorders other than RA (e.g. diabetes melli-
tus, chronic liver disease, chronic renal failure, etc.), and RA
patients with secondary ﬁbromyalgia. An informed consent
was obtained from patients participating in the study. The
study was approved by the local ethics committee of Sohag-
University scientiﬁc review board. Age, sex, disease duration,
swollen and tender joint counts of the RA patients were re-
corded. Visual analogue scale of pain (VAS), disease activity
index 28 (DAS28) [17], health assessment questionnaire
(HAQ) [18,19], erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) were used to assess disease activity.
Disease activity index 28 (DAS28) is a validated index of RA
disease activity. It consists of four measures: 28 tender
(TJC28) and swollen joint counts (SJC28), ESR, and the pa-
tient’s general health (GH) measured on a 100 mm visual ana-
logue scale. The disease modifying anti-rheumatic drugs(DMARDs) used in the study were methotrexate average dose
15 mg/week (either intravenous or subcutaneous), leﬂunomide
20 mg /day, and hydroxychloroquine 200–400 mg/day. Combi-
nation therapy with methotrexate and hydroxychloroquine
was used in the majority of our patients followed by metho-
trexate and leﬂunomide combination while monotherapy with
either methotrexate or leﬂunomide was used in some patients
with RA. Prednisolone was used for short term intermittent
control of disease activity in some RA patients.
2.1. Laboratory investigations
Serum RF and CRP concentrations were determined by immu-
no-nephelometry methods on Turbox nephelometer (Orion
diagnostica, Finland). The concentrations were expressed as
IU/ml for RF and mg/l for CRP. RF concentration P25 IU/
ml and CRP concentration P6 mg/l were considered positive
for RF and CRP respectively. The ESR was measured by the
Westergren method.
2.2. Hospital anxiety and depression scale (HADS)
The hospital anxiety and depression Scale (HADS; [12]) is de-
signed to measure both anxiety and depression in out-patient
populations. Each subscale comprises seven items which are
rated on a four-point scale and scored from 0 to 3 with total
scores therefore ranging from 0 to 21 for each subscale. Scores
between 0 and 7 represent ‘no case’; 8–10 indicate ‘possible
case’ and 11–21 suggest a ‘probable case of anxiety/depres-
sion’. These cut points have been validated against clinical
interviews with sensitivity and speciﬁcity around 0.80 [20].
In this study only the HADS-Depression subscale (HADS-
D) was used.
Statistical analysis: The results were analysed by IBM-SPSS
(version 19). Results were given as means and standard devia-
tion. Student’s t-test for continuous variables was used to
examine the signiﬁcance of differences between RA patients
with and without depression. P-value less than 0.05 was
regarded as signiﬁcant. The correlation between HADS-D
and age, disease duration, swollen and tender joint counts,
VAS, DAS28, HAQ, ESR and CRP was analysed by Pearson
correlation analyses. Linear regression analysis was used to
evaluate the effect of clinical and demographic characteristics
on HADS-D within the group of RA patients and depression.
P value < 0.1 was considered signiﬁcant.
3. Results
This study was carried on 170 RA patients (153 females and 17
males), their mean age was 43.75 ± 8.03, ranged from 34 to
68 years. The duration of RA was 3.74 ± 1.38, ranged from
2 to 9 years. The demographic and clinical characteristics of
patients with RA are shown in Table 1.
Of the RA patients, the prevalence of depression was
15.29% (26 RA patients). Statistically high signiﬁcant differ-
ences (P< 0.001) were found between depressed and non de-
pressed RA patients as regards HADS-D, VAS, DAS28,
number of tender joints, ESR and CRP. A statistically signif-
icant difference (P< 0.05) was found between both groups
as regards the DMARDs and RA duration. No signiﬁcant
difference (P> 0.05) was found between depressed and non
Table 3 Correlations between HADS-D and patients’ char-
acteristics in depressed RA patients (n= 26).
Characteristic (mean ± SD) r test P value
Age (years) 0.80 <0.001 (HS)
Disease duration (years) 0.75 <0.001 (HS)
VAS (0–100 mm) 0.53 0.005 (S)
Number of swollen joints 0.15 0.48 (NS)
Number of tender joints 0.13 0.53 (NS)
DAS28 score 0.49 0.01 (S)
HAQ score 0.60 <0.001 (HS)
ESR(mm/1st h) 0.08 0.69 (NS)
CRP(mg/l) 0.63 <0.001 (HS)
VAS, visual analogue scale of pain; DAS28, disease activity for 28
joint indices score; HAQ, health assessment questionnaire; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein.
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Figure 1a Correlation between HADS-D and age in RA patients
with depression.
Table 1 Demographic and clinical characteristics of RA
patients (n= 170).
Characteristic (Mean ± SD) RA patients (n= 170)
Age (years) 43.75 ± 8.03
Sex (F/M) 153/17
Disease duration in years 3.74 ± 1.38
Rheumatoid factor (%) 134 (78.8%)
VAS (0–100 mm) 39.41 ± 13.4
Number of swollen joints 1.21 ± 0.8
Number of tender joints 2.73 ± 0.99
DAS28 score 3.88 ± 0.35
HAQ score 1.45 ± 0.35
ESR (mm/1sthr) 24.14 ± 5.98
CRP (mg/l) 4.2 ± 3.67
HADS-D 5.85 ± 3.7
Medications
VAS, visual analogue scale of pain; DAS28, disease activity for 28
joint indices score; HAQ, health assessment questionnaire; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; HADS-D,
hospital anxiety and depression scale-depression subscale; MTX,
methotrexate; LEF, leﬂunomide; HCQ, hydroxychloroquine.
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len joints and HAQ score (Table 2).
In the depressed RA patients, positive signiﬁcant correla-
tions were found between HADS-D score and age, disease
duration, HAQ score, VAS, DAS28 score and CRP. However,
no signiﬁcant correlation was found between HADS-D score
and ESR, number of swollen and tender joints (Table 3)
(Fig. 1a and Fig. 1b).
On performing a linear regression analysis to assess the ef-
fect of clinical and demographic variables on HADS-D in RA
patients with depression, it was found that age, RA durationTable 2 Demographic and clinical characteristics of depressed and
Characteristic (mean ± SD) Depressed RA patients (n= 26) Non de
Sex (M/F) 4/22 13/131
Age (years) 43.92 ± 9.96 43.72 ±
Disease duration (years) 4.35 ± 1.94 3.63 ±
VAS (0–100 mm) 47.69 ± 21.41 37.92 ±
Number of swollen joints 1.42 ± 0.7 1.17 ±
Number of tender joints 1.92 ± 0.89 2.88 ±
DAS28 4.14 ± 0.45 3/83 ±
HAQ score 1.54 ± 0.21 1.43 ±
ESR (mm/1st h) 31.96 ± 3.84 22.73 ±
CRP (mg/l) 10.08 ± 3.42 3.14 ±
HADS-D 13.81 ± 2.32 4.41 ±
Medications:
MTX+HCQ 13 (50.0%) 96 (66.7
LEF +MTX 2 (7.7%) 24 (16.4
MTX 7 (26.9%) 12 (8.3%
LEF 4 (15.4%) 12 (8.3%
VAS: visual analogue scale of pain; DAS28: disease activity for 28 joint in
sedimentation rate; CRP: C-reactive protein; HADS-D: hospital anxiety
leﬂunomide; HCQ: hydroxychloroquine.
* Chi square was used.
** Student’s t test was used.and disease activity (DAS28) were signiﬁcant predictors of
depressive symptoms in RA patients (Table 4).non depressed RA patients (26 versus 144 patients respectively).
pressed RA patients (n= 144) t test**/Chi square* P value
0.99* 0.32 (NS)
7.68 0.12** 0.91 (NS)
1.23 2.49** 0.01 (S)
10.83 3.54** 0.001 (HS)
0.81 1.48** 0.14 (NS)
0.95 4.77** <0.001 (HS)
0.31 4.32** 0.001 (HS)
0.37 1.39** 0.16 (NS)
5.15 8.72** <0.001 (HS)
2.54 12.01** <0.001 (HS)
1.27 29.93** <0.001 (HS)
%)
%) 10.09* 0.02 (S)
)
)
dices score; HAQ: health assessment questionnaire; ESR: erythrocyte
and depression scale-depression subscale; MTX: methotrexate; LEF:
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Figure 1b Correlation between HADS-D and disease duration
in RA patients with depression.
Table 4 Linear regression analysis of clinical and demo-
graphic characteristics inﬂuencing HADS-D in RA patients
with depression (n= 26).
Model Beta t Sig.
Sex 0.02– 0.27– 0.79
Age (years) 0.23– 2.48– 0.01
Disease duration (years) 0.38 4.26 0.000
HAQ 0.09 1.25 0.21
DAS28 0.34 4.48 0.000
DAS28, disease activity for 28 joint indices score; HAQ, health
assessment questionnaire.
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male and female RA patients with depression except in the
ESR where the difference was highly signiﬁcant (Table 5).
As regards the DMARDs used for treatment of RA, no sig-
niﬁcant difference (P> 0.05) was found between different
groups of RA patients and depression (Table 6).
4. Discussion
RA is a systemic inﬂammatory disease that affects people both
physically and psychologically. Depression and anxiety fre-
quently occur in RA [21]. Concomitant depressive or anxiety
disorders in RA patients are associated with signiﬁcantly
poorer health-related quality of life [22]. Depression affects pa-
tients with RA beyond the burden of mental illness itself [23].Table 5 Comparison between male and female RA patients (4 vers
Characteristic (mean ± SD) Male (n= 4)
Age (years) 45.50 ± 13.48
Disease duration in years 4.75 ± 2.99
VAS (0–100 mm) 45 ± 12.91
Number of swollen joints 1 ± 0
Number of tender joints 2 ± 0.82
DAS28 score 4.2 ± 0.36
HAQ score 1.5 ± 0.08
ESR(mm/1st h) 37.25 ± 4.11
CRP(mg/l) 11 ± 3.46
HAD-D 13.25 ± 2.22
VAS, visual analogue scale of pain; DAS28, disease activity for 28 joint in
sedimentation rate; CRP, C-reactive protein; HADS-D, hospital anxietyIn the current study, prevalence of depression in patients
with RA was 15.29%. In other studies conducted on patients
with RA, major depressive disorder is common with a preva-
lence of 13–42% [15,24–27], at least double to four-times that
in the general population. The wide range in the prevalence of
depression in clinical studies of RA is likely due to the different
methods used for measuring depressive symptoms [23]. Race/
ethnicity is also a patient characteristic independently associ-
ated with depression in RA. Speciﬁcally, Asians with RA
report less depression [28] while Hispanics with RA, particu-
larly those who are not fully acculturated to mainstream Anglo
society, report more depression [29].
In this study, a statistically high signiﬁcant difference
(P< 0.001) was found between depressed and non depressed
RA patients as regards VAS, DAS28, number of tender joints,
ESR and CRP. A statistically signiﬁcant difference (P< 0.05)
was found between both groups as regards RA duration. No
signiﬁcant difference (P> 0.05) was found between depressed
and non depressed RA patients as regards gender, age, number
of swollen joints and HAQ score. These results show that pa-
tients with RA and co-morbid depression have worse health
outcomes [23]. In other words, poor clinical characteristics
and function are associated with subsequent depressive
symptoms [30]. In other studies, the duration of the rheumatic
disease does not appear to differ between patients with and
without depression [24,28].
In this study, no signiﬁcant correlation was found between
depression and gender while a positive signiﬁcant correlation
was found between depression and age. These results are con-
tradictory with other studies [13,15,25,31]. In those studies, fe-
male gender and younger age have well-known associations
with depression [23]. The reasons for this discrepancy between
our study and those studies may be related to the racial differ-
ences or to the small number of patients used in our study.
In our study, the disease duration was positively correlated
with the degree of depression which was consistent with Isik
et al. [27].
In the current study, a high positive signiﬁcant correlation
(P< 0.001) was found between depressed RA patients and
VAS. Our results were similar to those reported in other stud-
ies [32,33]. Not surprisingly, pain has been indicated as a
mechanism along the causal pathway for depression in those
with RA [34–36]. Furthermore, depression may confound
self-reports of pain [37]. Alternatively, pain in a patient
with RA and co-morbid depression could be diagnosticus 22 patients, respectively) with depression.
Female (n= 22) t test P value
43.64 ± 9.57 0.34 0.74 (NS)
4.27 ± 1.78 0.45 0.66 (NS)
48.18 ± 22.81 0.27 0.79 (NS)
1.5 ± 0.74 1.33 0.20 (NS)
1.91 ± 0.92 0.18 0.86 (NS)
4.13 ± 0.47 0.28 0.77 (NS)
1.54 ± 0.22 0.37 0.72 (NS)
31 ± 2.98 3.66 0.001 (HS)
9.91 ± 3.48 0.58 0.57 (NS)
13.91 ± 2.37 0.52 0.61 (NS)
dices score; HAQ, health assessment questionnaire; ESR, erythrocyte
and depression scale-depression subscale.
Table 6 The disease modifying anti-rheumatic drugs (DMARDs) used in RA patients with depression.
DMARDs RA+ depression (n = 26) HADS-D (Mean ± SD) Anova test P value
MTX+HCQ 13 (50.0%) (14.0 ± 2.55) 0.340 0.797 (NS)
LEF+MTX 2 (7.7%) (13.5 ± 2.12)
MTX 7 (26.9%) (14.14 ± 2.27)
LEF 4 (15.4%) (12.75 ± 2.22)
Total 26 (100.0%) (13.81 ± 2.32)
RA, rheumatoid arthritis; HADS-D, hospital anxiety and depression scale-depression subscale; DMARDs, disease modifying anti-rheumatic
drugs; MTX, methotrexate; LEF, leﬂunomide; HCQ, hydroxychloroquine.
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RA are misattributed to depression [38].
In this study, a high positive correlation (P< 0.001) was
found between HADS-D and HAQ scores, and a positive cor-
relation was found between HADS-D and DAS28 scores.
However, no signiﬁcant correlation was found between
HADS-D score and number of swollen and tender joints and
ESR. In other studies, there is conﬂicting evidence as to
whether or not RA disease activity measured by rheumatolo-
gist-documented swollen and tender joints affects depression.
Some studies show a positive correlation between depression
and RA disease activity scores [39–41] while others do not
[28,42]. Regardless of acute disease activity measures, there is
no doubt that limited function, as measured by the HAQ, is
a strong predictor of depression in patients with RA
[25,30,35,36,39,43–45]. Taking this one step further, loss of
valued activities beyond functional decline has been shown
to lead to depression [30,45]. This suggests that depression in
RA may not be caused by the acute clinical manifestations
of RA disease activity but instead caused by the long-term dis-
ability and joint damage associated with arthritis that results in
the loss of valued activities [23]. On the other hand, Rathbun
et al. suggest that depression may exacerbate pain and disease
activity and decrease the efﬁcacy of pharmacological (i.e. bio-
logic and non-biologic DMARDs) and some non-pharmaco-
logical (e.g. cognitive behavioural therapy) RA treatments
[46]. Further researches are needed to conﬁrm these results.
Finally, in this study, a high positive signiﬁcant correla-
tion was found between depression and CRP. In patients
with RA, there is conﬂicting evidence regarding the associa-
tion of CRP with depression [35,47]. Compared with non-
depressed individuals, depressed patients have activated
inﬂammatory pathways, including increased expression of
chemokines, adhesion molecules and cytokines [48]. Patients
with major depression have increased serum and/or plasma
concentrations of CRP [49,50], IL-6 [51,52] and proinﬂamma-
tory TNF-a [53–56].
Indeed, disease activity has been associated with depression
in RA both in cross-sectional [5,28,39] and in longitudinal re-
search [39]. It is important that the ﬁnding of a correlation be-
tween disease activity variables and depression does not prove
that depression is a direct consequence of disease activity. This
relation may be mediated by psychological factors or another
factor may be driving the relation. Depression may be an indi-
rect consequence of psychological mechanisms such as the bur-
den of symptoms and the uncontrollable nature of rheumatic
diseases and their unpredictable course that may make patients
more vulnerable to depression by mechanisms of learned help-
lessness [57].Rheumatologists must consider depression as a conse-
quence of both social context and biologic RA disease factors
in order to assess which aspects contribute the most to depres-
sion in patients with RA. In the next 10 years, rheumatologists
can substantially decrease depressive symptoms in their pa-
tients by addressing the root causes of depression: preventing
pain and disability, decreasing systemic inﬂammation and
designing and implementing evidence-based programs to miti-
gate the effects of depression in RA [7,58]. This entails moving
beyond associations to establish causal relationships that in
turn can lead to new and targeted therapies for depression in
patients with RA [23].
In conclusion, depression appears to be common, and there
is a need for greater recognition among rheumatologists of this
relatively neglected condition. Also, there is a need for an
acceptance of responsibility for identifying and managing it
appropriately. As a treatable condition with a high prevalence
that causes signiﬁcant suffering, we feel that a greater emphasis
on recognizing and treating depression in RA is warranted.
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